Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV23 revaccination in elderly: immunogenicity and safety
ChiCTR2100042000Phase 4Recruiting
- Sponsor
- Sichuan Center for Disease Control and Prevention
- Start
- Jan 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine in Pneumococcal pneumonia (PP), invasive pneumococcal disease (IPD) and bacterial pneumonia (2 arms), sponsored by Sichuan Center for Disease Control and Prevention. Primary endpoint: Antibody double growth rate. Started Jan 2021; status: recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)invasive pneumococcal disease (IPD)bacterial pneumonia
Beyond the preview
Go deeper on ChiCTR2100042000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042000.